Enzymatica announces today that the annual report 2015 is available on the company's web site www.enzymatica.se. The annual report is produced in Swedish. A brief English version of the annual report is estimated to be published on the web site within the next two-three weeks.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: firstname.lastname@example.org
Carl-Johan Wachtmeister, deputy communication officer Enzymatica
Tel: 0701-88 50 21 | E-post: email@example.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser Bankaktiebolag.